VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Linda Kaplan who wrote (2618)	11/19/1997 6:32:00 AM
From: BigKNY3	Read Replies (1) of 23519

Linda: Here's my take on last night's CNBC ED discussion that included the CEOs of Vivus and Zonagen, the ever-present Dr. Harin Padma-Nathan, and pharmaceutical analyst Hemandt Shah. No representative of Pfizer was on the panel: 1. The size of the ED market is still a big unknown but has the potential to be very large up to 40 million men. 2. The Vivus CEO felt that MUSE will benefit by the expanding ED market. He acknowledged that MUSE's market share is flat due to a problem supplying the product to meet the demand. 3. The Zonagen CEO felt Vasomax can compete with Viagra because of its marketing agreement with Schering. He defended accusations that clinical studies on Zonagen were flawed. 4. Dr. Padma-Nathan felt that all ED therapies will play an increased role in the near future and may be used in combination. 5. Hermandt Shah concluded that Pfizer was the best market play among the companies involved in ED because of its oral formulation and PFE's abilities as a marketing powerhouse. He especially likes PFE if its price goes lower. BigKNY3

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next